Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease

Arthritis and Rheumatism

Volumn 62, Issue 9, 2010, Pages 2796-2805

  Deuter, Christoph M E ^a   Zierhut, Manfred ^a   Möhle, Antje ^a   Vonthein, Reinhard ^b   Stübiger, Nicole ^a   Kötter, Ina ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PARACETAMOL; PREDNISOLONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR INHIBITOR; ALPHA INTERFERON;

ADULT; AGGRESSIVENESS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHCET DISEASE; BODY WEIGHT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE; EYE DISEASE; FATIGUE; FEMALE; FEVER; FIBROMYALGIA; FLU LIKE SYNDROME; FOLLOW UP; HAIR LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSYCHOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; SYMPTOM; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; BEHCET SYNDROME; COMPLICATION; DRUG ADMINISTRATION; MIDDLE AGED; RISK FACTOR; TIME; TREATMENT WITHDRAWAL; YOUNG ADULT;

ADULT; BEHCET SYNDROME; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UVEITIS; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 77955327167     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27581     Document Type: Article

References (34)

1. Mamo JG. The rate of visual loss in Behçet's disease. Arch Ophthalmol 1970;84:451-2.
2. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-74. (Pubitemid 127744665)
3. Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G. Prognosis in Behçet's disease. Ann Ophthalmol 1985;17:20-5.
4. BenEzra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986;70:589-92. (Pubitemid 16038279)
5. Palestine AG, Austin HA III, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986;314: 1293-8.
6. Whitcup SM, Salvo EC, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol 1994;118:39-45.
7. Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M. Behçet's disease: ocular effects and treatment. Prog Retin Eye Res 2008;27:111-36.
8. Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D. Efficacy and safety of systemic recombinant interferon-α in Behçet's disease. J Intern Med 1998;243:367-72. (Pubitemid 28255481)
9. Kotter I, Eckstein AK, Stubiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon α2a: a pilot study. Br J Ophthalmol 1998;82:488-94. (Pubitemid 28266417)
10. Stubiger N, Kotter I, Zierhut M. Complete regression of retinal neovascularisation after therapy with interferon α in Behçet's disease [letter]. Br J Ophthalmol 2000;84:1437-8.
11. Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, et al. Efficacy of interferon α-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000;8:293-301. (Pubitemid 32174750)
12. Stubiger N, Kotter I, Deuter C, Zierhut M. Behçet's disease: uveitis-therapy with interferon α2a - prospective clinical study in 33 patients. Klin Monatsbl Augenheilkd 2001;218:768-73. In German.
13. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon α-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-31.
14. Krause L, Turnbull JR, Torun N, Pleyer U, Zouboulis CC, Forster MH. Interferon α-2a in the treatment of ocular Adamantiades- Behcαet's disease. Adv Exp Med Biol 2003;528:511-9.
15. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-α therapy in patients with Behçet uveitis. Graefe's Arch Clin Exp Ophthalmol 2006;244:1692-5. (Pubitemid 44830831)
16. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Le Thi Huong D, et al. Efficacy of interferon α in the treatment of refractory and sight-threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;71:335-9.
17. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008;67:1656-62.
18. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease [review]. Lancet 1990;335:1078-80.
19. Kotter I, Aepinus C, Graepler F, Gartner V, Eckstein AK, Stubiger N, et al. HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon α. Ann Rheum Dis 2001; 60:83-6. (Pubitemid 32038962)
20. BenEzra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P. Uveitis Scoring System. Berlin: Springer; 1991.
21. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
22. Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte α-interferon. Arch Dermatol Res 1986;278:335-6. (Pubitemid 16096033)
23. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon α-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71.
24. Krause L, Altenburg A, Pleyer U, Kohler AK, Zouboulis CC, Forster MH. Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-α-2a. J Rheumatol 2008;35:896-903. (Pubitemid 351747134)
25. Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, et al. Long-term efficacy and safety of low-dose interferon α2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol 2008;146:837-44.
26. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35. (Pubitemid 38496041)
27. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behçet disease. Ophthalmology 1995;102:317-21.
28. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60-76.
29. Krause L, Kohler AK, Altenburg A, Papoutsis N, Zouboulis CC, Pleyer U, et al. Ocular involvement is associated with HLA-B51 in Adamantiades- Behçet's disease. Eye (Lond) 2009;23:1182-6.
30. Lewis KA, Graham EM, Stanford MR. Systematic review of ethnic variation in the phenotype of Behçet's disease. Scand J Rheumatol 2007;36:1-6. (Pubitemid 46572905)
31. Hauschild A, Kaehler KC, Schaefer M, Fluck M. Interdisciplinary management recommendations for toxicity associated with interferon- α therapy. J Dtsch Dermatol Ges 2008;6:829-37.
32. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8.
33. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005;26:83-92. (Pubitemid 44781873)
34. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005;52:2478-84.